Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Common pain killers may blunt the effect of flu shots

With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.

4 Nov 2009

Financial results for third-quarter 2009 announced by Combinatorx

CombinatoRx, Incorporated today reported financial results for the third quarter ended September 30, 2009.

3 Nov 2009

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.

3 Nov 2009

Rigel Pharmaceuticals announces financial results for the third quarter of 2009

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

3 Nov 2009

Caucasian women may suffer from RLS up to four times more than African-American women

New research shows that Caucasian women may suffer from restless legs syndrome (RLS), a sleep disorder characterized by the strong urge to move the legs, up to four times more than African-American women. The study, presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that, overall, non-African-American (NAA) patients experienced RLS four times more often than African-Americans (AA).

3 Nov 2009

Adults who experienced physical abuse as children at a higher risk of osteoarthritis, says study

Adults who had experienced physical abuse as children have 56 per cent higher odds of osteoarthritis compared to those who have not been abused, according to a new study by University of Toronto researchers.

3 Nov 2009

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. A study led by Dr. Christian A Pineau, Co-Director of the Lupus and Vasculitis clinic at the MUHC, has clearly linked skin damage and rashes to smoking in people with systemic lupus erythematosus (SLE). The study was published in a recent issue of the Journal of Rheumatology.

3 Nov 2009

Appropriate treatment for children with meniscal tears leads to high success rate: Study

The meniscus is a rubber-like, crescent moon-shaped cartilage cushion that sits between the leg and thigh bone. Each knee has two menisci: one on the inside of the knee joint and one on the outside. In recent years, more children have been diagnosed with tears to this area (meniscal tears); however, according to a literature review published in the November 2009 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), prospects for a full recovery are high.

3 Nov 2009

$Aggressive osteoporosis prevention could reduce hip fracture rate in the U.S. by 25%: Study$

Aggressive osteoporosis prevention could reduce hip fracture rate in the U.S. by 25%: Study

Aggressively managing patients at risk for osteoporosis could reduce the hip fracture rate in the United States by 25 percent, according to a Kaiser Permanente study published in the November issue of the Journal of Bone & Joint Surgery. The first step must be a more active role by orthopedic surgeons in osteoporosis disease management, researchers say.

3 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

Ligand Pharmaceuticals amends license agreement with Exelixis

Ligand Pharmaceuticals Incorporated has amended its license agreement with Exelixis, Inc. as a result of which Ligand is now entitled to receive royalties on net sales of future products from a mineralocorticoid receptor program and a one-time $75,000 payment for providing access to certain patent rights.

2 Nov 2009

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's automated SQiDworks(TM) Diagnostics Platform and its multiplexed IgXPLEX(TM) rheumatoid arthritis (RA) assay for marketing in the United States.

2 Nov 2009

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.

2 Nov 2009

HGS and GSK announce results from phase III clinical trials of BENLYSTA

Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology. Both trials succeeded in meeting their primary endpoints, which should make BENLYSTA eligible for approval by the U.S. Food and Drug Administration (FDA).

2 Nov 2009

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.

2 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Individualized MicroNutrient Testing for patients

In response to the current trend toward personalized medicine, the Beaumont Weight Control Center, affiliated with Beaumont Hospitals, a major Detroit-area health system, now offers individualized MicroNutrient Testing for patients.

31 Oct 2009

Data from multiple clinical and preclinical studies evaluating Hematide announced

Affymax, Inc. and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients.

31 Oct 2009

Patients on immunosuppressant medication can receive H1N1 vaccine in the form of shots

The Centers for Disease Control and Prevention (CDC) have classified all children, 6-months to 24-years, one of the high risk groups for contracting the H1N1 (swine) flu, and recommend this population receive the H1N1 vaccine for immunity against the disease.

30 Oct 2009

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Common pain killers may blunt the effect of flu shots

Financial results for third-quarter 2009 announced by Combinatorx

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

Rigel Pharmaceuticals announces financial results for the third quarter of 2009

Caucasian women may suffer from RLS up to four times more than African-American women

Adults who experienced physical abuse as children at a higher risk of osteoarthritis, says study

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

Appropriate treatment for children with meniscal tears leads to high success rate: Study

Aggressive osteoporosis prevention could reduce hip fracture rate in the U.S. by 25%: Study

Interim data from Schering-Plough's narlaprevir Phase IIa study

Ligand Pharmaceuticals amends license agreement with Exelixis

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

HGS and GSK announce results from phase III clinical trials of BENLYSTA

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Amgen publishes Phase 3 study results of Aranesp

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Individualized MicroNutrient Testing for patients

Data from multiple clinical and preclinical studies evaluating Hematide announced

Patients on immunosuppressant medication can receive H1N1 vaccine in the form of shots

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in